Janssen Adds Yuhan’s Lazertinib to its Oncology Pipeline in a US$1.25 B Deal

By Jawala Prasad & Michelle Liu

Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)

Published: 20 Nov-2018

DOI: 10.3833/pdr.v2018.i11.2372     ISSN: 1756-7874

Section: Research & Development



Just a few weeks after ending four oncology deals worth at least US$2...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details